In a variety of cancer models, R39 was found to completely inhibit the phosphorylation of 4E-BP1, S6K1 and AKT, and it showed good oral and pharmacodynamic effects and highly potent antitumor effects in a xenograft model that was resistant to rapamycin [82]. This evidence concerns the gene RPS6KB1 and cancer.